Valdespino-Gómez VM

Language: Spanish
References: 19
Page: 195-200
PDF size: 231.49 Kb.

ABSTRACT

In the first part of the present paper, the basis and importance of translational medicine (TM) on the current status of quality of health care is discussed. This is exemplified by the application and benefit of translational oncology and personalized oncology in cancer patients as a model of TM. The second part of this article discusses the processes that have allowed the expansion of TM in developed countries and, likewise, the global conditions that have disabled the installation and expansion of TM in Mexico. The author suggests the establishment of Units of Translational Research in third-level hospitals, which will allow the formal initiation of TM in Mexico. The author concludes that the policy of translational research in regard to national public health care is currently necessary. This policy requires the participation of government, national medical academies and societies, health sector medical centers, medical and research educators, centers of investigation, pharmaceutical and biotechnology industries, medical and biomedical physicians, and any other persons or entities who participate in the implicit improvement of the level of medical care. The installation of translational research units located in hospitals represents a common benefit for the entire society and, specifically, for patients, through the generation of a healthcare system with a higher scientific level, as well as higher quality of care.

REFERENCES

1. Littman BH, Di Mario L, Plebani M, Marincola FM. What’s next in translational medicine? Clin Sci 2007;112:217-227.

2. Sussman S, Valente TW, Rohrbach LA, Skara S, Pentz MA. Translation in the health professions: converting science into action. Eval Health Prof 2006;29:7-32.

3. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 2008;44:2707-2713.

4. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452:553-562.

5. Valdespino GV. Elementos necesarios para el ejercicio moderno de las ciencias médicas. Cir Cir 2003;71:347-349.

6. Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med 2005;11:705-708.

7. Díaz-Rubio GE. La investigación traslacional en oncología: retos y oportunidades. An R Acad Med 2008;121:105-120.

8. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007;8:177-185.

9. Valdespino GVM, Valdespino CVE. Terapia molecular en pacientes que no responden a los tratamientos convencionales. Gac Med Mex 2008;144:333-344.

10. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trail. Future Oncol 2008;4:603-610.

11. Cardoso F, Van´t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26:729-735.

12. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph node in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.

13. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-552.

14. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological appplications in medicine. Curr Opin Biotechnol 2007;18:26-30.

15. Lammars T, Hennink WE, Storm G. Tumor-targeted nanomedicines: principles and practice. BJC 2008;99:392-397.

16. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009;15:153-172.

17. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-589.

18. Suzuki R, Rao P, Sasaguri S. Current status and future of target-based therapeutics. Curr Cancer Drug Targets 2007;7:273-284.

19. Torkamani A, Verkhivker G, Schork NJ. Cancer driver mutations in protein kinases genes. Cancer Lett 2009;281:117-127.